Navigation Links
Neurocrine Biosciences Reports Fourth Quarter And Year End 2012 Results
Date:2/8/2013

enues under the Company's elagolix collaboration agreement. Revenues for the year ended December 31, 2012 were $53.1 million, compared with $77.4 million for 2011. The $24.3 million decrease in revenue is primarily due to $30 million in milestones achieved under the Company's elagolix collaboration agreement during the third quarter of 2011.

Research and development expenses increased to $9.1 million during the fourth quarter of 2012 compared with $8.0 million for the same period in 2011. For the year ended December 31, 2012, research and development expenses were $37.2 million, compared to $31.0 million for 2011. The increase in research and development expenses is primarily driven by Phase IIb development expenses for the VMAT2 program, coupled with increased compensation related costs, primarily due to equity based compensation.

General and administrative expenses increased to $3.3 million during the fourth quarter of 2012 compared with $2.7 million for the same period last year. For the year ended December 31, 2012, general and administrative expenses were $13.4 million, compared to $12.5 million for 2011. The increase in year-to-date general and administrative expenses is primarily related to higher equity based compensation costs.

2013 Financial GuidanceThe Company expects to have a net cash burn from operations of approximately $50 to $55 million in 2013. Revenue is expected to approximate $3 million which consists solely of the amortization of up-front license fees. Expenses for 2013 should approximate $55 to $60 million. Net loss for 2013 is expected to be $50 to $55 million, or $0.75 to $0.83 loss per share based on 66.5 million basic shares outstanding. The Company expects to end 2013 with in excess of $130 million in cash, investments and receivables.

Pipeline HighlightsElagolix UpdateAbbVie is currently conducting the initial Phase III study of elagolix for endometriosis, the Violet Petal Study. The study is a 24-week
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Neurocrine Biosciences To Present At The 24th Annual Piper Jaffray Healthcare Conference
2. Neurocrine Biosciences Reports Third Quarter 2012 Results
3. Neurocrine Biosciences Reports Second Quarter 2012 Results
4. Neurocrine Biosciences to Present at The 24th Annual Roth Conference
5. Neurocrine Biosciences to Present at the Citi 2012 Global Health Care Conference
6. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
7. Sangamo BioSciences Announces Fourth Quarter And Full Year 2012 Conference Call And Webcast
8. IntelliCell BioSciences Announces the Addition of Harry Fisch, MD as Director of Urology
9. Avelas Biosciences Closes $7.65 Million Series A, Advances Real-Time Tumor Visualization Technology Toward Development
10. Pressure BioSciences, Inc. Appoints Conrad F. Mir as Chief Financial Officer
11. IntelliCell BioSciences Announces Research Agreement with the New Jersey Center for Biomaterials at Rutgers-The State University of New Jersey
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... , October 1, 2014 ... to software invited to engage around the theme, ,Commercial ...     Elsevier , ... products and services, will host a gathering of some ... issues and trends impacting healthcare today and in the ...
(Date:9/30/2014)... , Sept. 30, 2014 Pacific Northwest ... Summary Global Markets Direct,s, ,Pacific Northwest ... provides an overview of the Pacific Northwest Biotechnology, ... report provides comprehensive information on the current therapeutic ... with comparative analysis at various stages, therapeutics assessment ...
(Date:9/30/2014)... Proove Biosciences , the commercial ... announce a new genetic test built upon research from ... Test will provide physicians with an objective way ... levels are stratified between individuals. With this new test, ... has a genetic predisposition that will affect their pain ...
(Date:9/30/2014)... Genedata, a leading provider ... and related life science research, today announced ... Selector as its host-pathogen data analysis platform ... a European consortium dedicated to improving the ... anti-fungal drug therapies. Genedata Selector supports this ...
Breaking Biology Technology:Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 3Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 2Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 3Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 2FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 3
... DIEGO, Jan. 29 BioMed Realty Trust, Inc.,(NYSE: BMR ... quarter,and year ended December 31, 2007 after the market closes ... Chief Executive Officer, and Kent Griffin,Chief Financial Officer, will host ... February 29, 2008 to discuss the company,s,financial results and operations ...
... Jan. 29 QED International Associates, Inc,administrator ... 20 underlying,indexes for the HealthShares(TM) Exchange-Traded Funds, ... trading on Thursday January 31, 2008 KV,Pharmaceutical ... (Nasdaq: ARXT ) in the HealthShares(TM) ...
... to be Highlighted at Molecular Imaging Conference, ... Inc., (OTC Bulletin Board: IMDS) a pioneer in ... 2008, January 28 - 31,2008, in Dubai, United ... CD89., (Logo: http://www.newscom.com/cgi-bin/prnh/20040412/IMDSLOGO ), ...
Cached Biology Technology:BioMed Realty Trust To Report 2007 Fourth Quarter and Year-End Results 2QED International Associates Announces Changes to the HealthShares(TM) Composite and HealthShares(TM) Respiratory/Pulmonary Indexes 2Imaging Diagnostic Systems Exhibits at Major Middle East Health Conference 2Imaging Diagnostic Systems Exhibits at Major Middle East Health Conference 3
(Date:9/30/2014)... nature as something that we enjoy when we visit a ... we think of ourselves as a part of nature? A ... a house? , The answers to these questions reflect ... our speech and in cultural artifacts. , A new Northwestern ... American Indian Center of Chicago and the Menominee tribe of ...
(Date:9/30/2014)... professor and Howard Hughes Medical Institute investigator, and ... recipients in the 2014 round of grants from ... BRAIN (Brain Research through Advancing Innovative Neurotechnologies) Initiative ... September 30, provides more than $3 million in ... , The BRAIN Initiative, launched last year, is ...
(Date:9/30/2014)... German . ... foods in the world. Because they grow underground, people use ... smell of truffles is not only of interest to gourmets. ... of the Goethe University Frankfurt have discovered that the smell ... are trapped inside truffle fruiting bodies. , White truffles from ...
Breaking Biology News(10 mins):The cultural side of science communication 2Salk scientists receive $3 million for BRAIN Initiative grant 2On the trail of the truffle flavor 2
... discovered in the open ocean may force scientists to rethink ... ecosystems. A paper describing the new findings appears in ... A research team led by Jonathan Zehr, a marine ... new microbe by analyzing its genetic material, even though researchers ...
... unveils new equipment to make cancer treatment safer ... National Physical Laboratory (NPL) today will help improve the ... electron linear accelerator (linac) will help ensure patients are ... treats cancer, by using ionising radiation such as high-energy ...
... lives in remarkable ways by providing food and water, ... they are experiencing loss and degradation on a massive ... water for long enough periods to support plants that ... wet year-round. The areas include marshes, swamps, bogs and ...
Cached Biology News:Mysterious microbe plays important role in ocean ecology 2Mysterious microbe plays important role in ocean ecology 3NPL unveils new equipment to make cancer treatment safer 2Value of satellites recognized for conserving wetlands 2Value of satellites recognized for conserving wetlands 3
Mouse polyclonal antibody raised against a partial recombinant TSEN2. NCBI Entrez Gene ID = 80746...
Mouse polyclonal antibody raised against a partial recombinant AGTRAP. NCBI Entrez Gene ID = 57085...
Mouse monoclonal antibody raised against a partial recombinant RAB11B. NCBI Entrez Gene ID = RAB11B...
... Mouse polyclonal antibody raised against ... Immunogen: SF3B2 ... a.a) partial recombinant protein with ... Accession Number: NM_006842 ...
Biology Products: